Literature DB >> 26684332

p53 and Meduloblastoma.

Vijay Ramaswamy1, Carolina Nör2, Michael D Taylor3.   

Abstract

Our understanding of medulloblastoma biology has increased dramatically over the past decade, in part a result of the recognition that there exists tremendous intertumoral heterogeneity not apparent by morphology alone. A particular area that significantly changed our approach to medulloblastoma has been an increased understanding of the role of p53. A role for p53 in medulloblastoma has been established over the past 20 years, however, not until recently has its significance been identified. Recent developments in the understanding of intertumor heterogeneity has clarified the role of TP53 mutations, as the importance of TP53 mutations is highly dependent on the molecular subgroup of medulloblastoma, with TP53 mutant Sonic Hedgehog medulloblastomas forming an extremely high-risk group of patients. As such, there is now a tremendous push to understand the role that p53 plays in treatment resistance of medulloblastoma. In this review, we will summarize the current understanding of p53 in medulloblastoma drawn primarily from recent advances in integrated genomics.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26684332      PMCID: PMC4743072          DOI: 10.1101/cshperspect.a026278

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  64 in total

1.  Adult medulloblastoma comprises three major molecular variants.

Authors:  Marc Remke; Thomas Hielscher; Paul A Northcott; Hendrik Witt; Marina Ryzhova; Andrea Wittmann; Axel Benner; Andreas von Deimling; Wolfram Scheurlen; Arie Perry; Sidney Croul; Andreas E Kulozik; Peter Lichter; Michael D Taylor; Stefan M Pfister; Andrey Korshunov
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

3.  Pleiotropic role for MYCN in medulloblastoma.

Authors:  Fredrik J Swartling; Matthew R Grimmer; Christopher S Hackett; Paul A Northcott; Qi-Wen Fan; David D Goldenberg; Jasmine Lau; Selma Masic; Kim Nguyen; Slava Yakovenko; Xiao-Ning Zhe; Heather C Flynn Gilmer; Rodney Collins; Mai Nagaoka; Joanna J Phillips; Robert B Jenkins; Tarik Tihan; Scott R Vandenberg; C David James; Kohichi Tanaka; Michael D Taylor; William A Weiss; Louis Chesler
Journal:  Genes Dev       Date:  2010-05-15       Impact factor: 11.361

4.  Histological subtype of medulloblastoma frequently changes upon recurrence.

Authors:  Julia Pöschl; Arend Koch; Ulrich Schüller
Journal:  Acta Neuropathol       Date:  2015-02-08       Impact factor: 17.088

Review 5.  FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma.

Authors:  Vijay Ramaswamy; Paul A Northcott; Michael D Taylor
Journal:  Cancer Genet       Date:  2011-11

6.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Authors:  James Kim; Blake T Aftab; Jean Y Tang; Daniel Kim; Alex H Lee; Melika Rezaee; Jynho Kim; Baozhi Chen; Emily M King; Alexandra Borodovsky; Gregory J Riggins; Ervin H Epstein; Philip A Beachy; Charles M Rudin
Journal:  Cancer Cell       Date:  2013-01-03       Impact factor: 31.743

7.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-01       Impact factor: 12.300

9.  Altered neural cell fates and medulloblastoma in mouse patched mutants.

Authors:  L V Goodrich; L Milenković; K M Higgins; M P Scott
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

10.  Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics.

Authors:  Elina Levina; Moshe Oren; Avri Ben-Ze'ev
Journal:  Oncogene       Date:  2004-05-27       Impact factor: 9.867

View more
  18 in total

1.  TP53 Mutation, MYCN Amplification, and Large Cell/Anaplastic Histology in Medulloblastoma.

Authors:  Anirban Das; Lateef Zameer; Sushant Vinarkar; Manish Singh; Mayur Parihar; Neeraj Arora; Aditi Chandra; Rimpa Basu Achari
Journal:  Indian J Pediatr       Date:  2017-11-15       Impact factor: 1.967

2.  Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.

Authors:  BaoHan T Vo; Chunliang Li; Marc A Morgan; Ilan Theurillat; David Finkelstein; Shaela Wright; Judith Hyle; Stephanie M C Smith; Yiping Fan; Yong-Dong Wang; Gang Wu; Brent A Orr; Paul A Northcott; Ali Shilatifard; Charles J Sherr; Martine F Roussel
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

3.  Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway.

Authors:  Aisha Naeem; Varsha Harish; Sophie Coste; Erika M Parasido; Muhammad Umer Choudhry; Lawrence F Kromer; Chukuemeka Ihemelandu; Emanuel F Petricoin; Mariaelena Pierobon; Muhammad Saad Noon; Venkata Mahidhar Yenugonda; Maria Avantaggiati; Gary M Kupfer; Stanley Fricke; Olga Rodriguez; Chris Albanese
Journal:  Mol Cancer Res       Date:  2021-10-11       Impact factor: 6.333

4.  A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.

Authors:  Jezabel Rodriguez-Blanco; Bin Li; Jun Long; Chen Shen; Fan Yang; Darren Orton; Sara Collins; Noriyuki Kasahara; Nagi G Ayad; Heather J McCrea; Martine F Roussel; William A Weiss; Anthony J Capobianco; David J Robbins
Journal:  Clin Cancer Res       Date:  2018-11-28       Impact factor: 12.531

Review 5.  Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

Authors:  Vijay Ramaswamy; Marc Remke; Eric Bouffet; Simon Bailey; Steven C Clifford; Francois Doz; Marcel Kool; Christelle Dufour; Gilles Vassal; Till Milde; Olaf Witt; Katja von Hoff; Torsten Pietsch; Paul A Northcott; Amar Gajjar; Giles W Robinson; Laetitia Padovani; Nicolas André; Maura Massimino; Barry Pizer; Roger Packer; Stefan Rutkowski; Stefan M Pfister; Michael D Taylor; Scott L Pomeroy
Journal:  Acta Neuropathol       Date:  2016-04-04       Impact factor: 17.088

6.  Bridging the Gap: Exploring the Impact of Hospital Isolation on Peer Relationships Among Children and Adolescents with a Malignant Brain Tumor.

Authors:  Jami-Leigh Sawyer; Faye Mishna; Eric Bouffet; Michael Saini; Randi Zlotnik-Shaul
Journal:  Child Adolesc Social Work J       Date:  2021-05-18

7.  Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors.

Authors:  Savita Sankar; Ethan Patterson; Emily M Lewis; Laura E Waller; Caili Tong; Joshua Dearborn; David Wozniak; Joshua B Rubin; Kristen L Kroll
Journal:  Genes Cancer       Date:  2017-09

Review 8.  Evasion of cell senescence in SHH medulloblastoma.

Authors:  Lukas Tamayo-Orrego; Shannon M Swikert; Frédéric Charron
Journal:  Cell Cycle       Date:  2016-05-26       Impact factor: 4.534

Review 9.  Medulloblastoma in the Molecular Era.

Authors:  Claudia Miranda Kuzan-Fischer; Kyle Juraschka; Michael D Taylor
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01

10.  TAp73 is a marker of glutamine addiction in medulloblastoma.

Authors:  Maria Victoria Niklison-Chirou; Ida Erngren; Mikael Engskog; Jakob Haglöf; Daniel Picard; Marc Remke; Phelim Hugh Redmond McPolin; Matthew Selby; Daniel Williamson; Steven C Clifford; David Michod; Michalis Hadjiandreou; Torbjörn Arvidsson; Curt Pettersson; Gerry Melino; Silvia Marino
Journal:  Genes Dev       Date:  2017-09-26       Impact factor: 12.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.